PALATIN TECHNOLOGIES INC (PTN) Stock Price, Forecast & Analysis
USA - NYSEARCA:PTN - US6960775020 - Common Stock
PTN Key Statistics, Chart & Performance
The current stock price of PTN is 0.0941 USD. In the past month the price decreased by -78.71%. In the past year, price decreased by -95.89%.
PTN Latest News, Press Relases and Analysis
PTN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B | ||
| INCY | INCYTE CORP | 16.39 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 37.03 | 15.35B |
Related stock screener links
About PTN
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 30 full-time employees. The firm is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.
Company Info
PALATIN TECHNOLOGIES INC
4B Cedar Brook Drive
Cranbury NEW JERSEY 08512 US
CEO: Carl Spana
Employees: 30
Phone: 16094952200
PALATIN TECHNOLOGIES INC / PTN FAQ
What does PTN do?
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 30 full-time employees. The firm is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.
Can you provide the latest stock price for PALATIN TECHNOLOGIES INC?
The current stock price of PTN is 0.0941 USD. The price decreased by -44.65% in the last trading session.
What is the dividend status of PALATIN TECHNOLOGIES INC?
PTN does not pay a dividend.
How is the ChartMill rating for PALATIN TECHNOLOGIES INC?
PTN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists PTN stock?
PTN stock is listed on the NYSE Arca exchange.
How is the valuation of PALATIN TECHNOLOGIES INC (PTN) based on its PE ratio?
PALATIN TECHNOLOGIES INC (PTN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).
Can you provide the number of employees for PALATIN TECHNOLOGIES INC?
PALATIN TECHNOLOGIES INC (PTN) currently has 30 employees.
PTN Technical Analysis
PTN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PTN. PTN has a bad profitability rating. Also its financial health evaluation is rather negative.
PTN Financial Highlights
Over the last trailing twelve months PTN reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS increased by 40.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -625.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTN Forecast & Estimates
5 analysts have analysed PTN and the average price target is 7.14 USD. This implies a price increase of 7487.67% is expected in the next year compared to the current price of 0.0941.
For the next year, analysts expect an EPS growth of 51.7% and a revenue growth -100% for PTN